Artelo Biosciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

EQUITY (Detail Narrative)

EQUITY (Detail Narrative) - USD ($)	1 Months Ended				3 Months Ended					9 Months Ended
EQUITY (Detail Narrative) - USD ($)	Aug. 26, 2026	May 26, 2026	Mar. 27, 2026	Jan. 30, 2026	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Aug. 28, 2026	Jan. 29, 2026	Dec. 31, 2025
Preferred stock, par value					$ 0.001					$ 0.001				$ 0.001
Aggregate value					$ 2,862,000	$ 174,000	$ 10,033,000	$ 3,310,000	$ 1,081,000
Gross proceeds from the offering if Warrants are fully exercised for cash										$ 237,000	$ 132,000
Preferred stock, shares authorized					23,148					23,148				23,148
Preferred stock, shares issued					0					0				0
Preferred stock, shares outstanding					0					0				0
Intrinsic value of the warrants					$ 0					$ 0
Common stock, par value					$ 0.001					$ 0.001				$ 0.001
Common stock, shares authorized					55,555,556					55,555,556				55,555,556
Common stock, shares issued					937,177					937,177				74,779
Common stock, shares outstanding					937,177					937,177				74,779
Proceeds from Issuance or Sale of Equity										$ 75,000,000
Reverse stock split, description	(1-for-9)
Valuation [Member]
Options granted										14,401
Option granted, value										$ 533,000
Stock option expense, unamortized					$ 500,000					500,000
Options outstanding, intrinsic value					0					$ 0				$ 0
Valuation [Member] \| Related Parties [Member]
Options granted										7,535
Option granted, value										$ 279,000
Stock option expense, unamortized					$ 243,000					$ 243,000
At The Market Offering Agreement [Member]
Exercise price, per share		$ 0.001
Number of shares issued, shares										432,062
Proceeds from Issuance or Sale of Equity		$ 6,530,000								$ 3,037,000
Warrants outstanding										784,424
Bottom [Member]
Common stock, shares authorized					166,666,667					166,666,667		55,555,556
Top [Member]
Common stock, shares authorized					500,000,000					500,000,000		500,000,000
2018 Equity Incentive Plan [Member]
Common stock, shares issued					23,644					23,644
Common stock reserved for future issuance													11,216
Common stock, shares available to be issued					742					742
Equity Agreement [Member]
Exercise price, per share				$ 0.027
Payments for repurchase of common stock										2,223
Payments for repurchase of common Stock amount										$ 14
Initial commitment amount				$ 25,000
Additional initial commitment amount				$ 25,000
Number of shares issued, shares				3,927
Number of pre funded warrants issued, shares				6,900
Number of pre funded warrants purchased				6,900
Aggregate value				$ 500
Cash fee, percent			8.00%
Number of warrants issued to purchase common stock			28,344
Warrants exercise price			$ 38.8125
Gross proceeds from the offering			$ 10,997,000
Gross proceeds from the offering if Warrants are fully exercised for cash			31,400,000
Net proceeds from the offering			$ 10,033,000
Description of pre-funded warrants			(i) 9,000 shares (the “Shares”) of the Company’s common stock at $31.05 per share, (ii) pre-funded warrants to purchase 345,268 shares of common stock at an exercise price of $0.009 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 708,536 shares of common stock at an exercise price of $28.80 per share (the “Common Warrants”). The Pre-Funded Warrants and the Common Warrants are collectively referred to herein as the “Warrants” and the shares issuable upon such Warrants, the “Warrant Shares.” Each Share or, at the election of the Purchaser in lieu of Shares, each Pre-Funded Warrant was issued and sold along with two Common Warrants. The combined purchase price for the securities was (i) $31.05 per Share and two Common Warrants, and (ii) $31.041 per Pre-Funded Warrant and two Common Warrants. The offering closed on March 30, 2026